Cardiff Oncology CMO Katherine Ruffner departs; Sandra Silberman named interim senior medical advisor

Cardiff Oncology, Inc.

CMO Katherine Ruffner leaving April 22, 2022; will provide transitional support.
Separation agreement includes $75,000 cash payment, base salary, unused PTO, expense reimbursement.
Sandra Silberman, former chief medical advisor (2017-2021), returns as senior medical advisor on interim basis.
Silberman has experience at Pfizer, Novartis, Eisai; currently CMO at Moleculin Biotech and CNS Pharmaceuticals.
CEO states clinical trials remain on track and on schedule.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Sandra L. Silberman, M.D., Ph.D.

senior medical advisor

CRDF · Cardiff Oncology, Inc.

Filed: April 12, 2022, 7:59 PM ET

Sandra L. Silberman, M.D., Ph.D., who previously acted as a chief medical advisor to Cardiff Oncology from June 2017 to July 2021, has agreed to serve as the Company’s senior medical advisor and oversee its clinical trials and clinical operations team on an interim basis.

Departed (interim)

Katherine Ruffner, M.D.

Chief Medical Officer

CRDF · Cardiff Oncology, Inc.

Effective: 2022-04-22
Successor: Sandra L. Silberman, M.D., Ph.D.
Filed: April 12, 2022, 7:59 PM ET

On April 12, 2022, Cardiff Oncology, Inc. (the “Company”) announced that Katherine Ruffner, M.D., the Company’s Chief Medical Officer, will be leaving the Company on April 22, 2022, to pursue a new opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Sandra L. Silberman, M.D., Ph.D. was appointed as senior medical advisor at Cardiff Oncology, Inc..

Action: appointed
Role: senior medical advisor

Exact text from the filing

Sandra L. Silberman, M.D., Ph.D., who previously acted as a chief medical advisor to Cardiff Oncology from June 2017 to July 2021, has agreed to serve as the Company’s senior medical advisor and oversee its clinical trials and clinical operations team on an interim basis.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Katherine Ruffner, M.D. resigned as Chief Medical Officer at Cardiff Oncology, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On April 12, 2022, Cardiff Oncology, Inc. (the “Company”) announced that Katherine Ruffner, M.D., the Company’s Chief Medical Officer, will be leaving the Company on April 22, 2022, to pursue a new opportunity.

View on SEC.gov

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-008987

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.